Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production.

The patient enrollment is now finalized in the randomized double-blind placebo-controlled phase II study testing the safety and efficacy of direct injection of ASCs produced using Cell2Cure´s patented technology into the lacrimal gland in 40 patients with Sjögren’s syndrome.

The follow-up is ongoing, and the final results are expected early 2023.